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We describe herein a novel synthetical application of shikimic acid, which consist of its 
transformation into (3R,4S,5R,7S)-7-(hydroxymethyl)azepane-3,4,5-triol. 
 
INTRODUCTION. 
With the breakthroughs in Glycobiology, glycosidases have received considerable 
attention due to their use as biochemical tools and involvement in several important 
biological processes, such as digestion, the biosynthesis of glycoproteins and the 
catabolism of glycoconjugates.1 Accordingly, glycosidase inhibitors have been 
extensively investigated over the last two decades on account of their potential as 
therapeutic agents.1 Indeed, some examples have already been tested or approved for 
use in the treatment of various diseases such as Gaucher’s disease, diabetes, cancer and 
viral infections – including AIDS. This situation has led to considerable effort in recent 
years aimed at understanding the structural types, mechanisms of action and synthesis 
of glycosidase inhibitors. 
The most prominent glycosidase inhibitors are imino sugars,2 which are 
polyhydroxylated nitrogen-containing ring skeleton analogues of furanoses or pyranoses 
in which the ring oxygen is replaced by nitrogen.8 A great deal of synthetic effort has 
been focused on the preparation of substituted pyrrolidine or piperidine mimics of the 
corresponding sugars, including nojirimycin (1a) and deoxynojirimycin (1b), the former 
being an imino sugar that can be regarded as the result of replacing the ring oxygen of 
D-glucose by a nitrogen.3 More recently, some higher homologues like azepanes (2) 
have been found to inhibit glycosidases, prompting efforts directed towards their 
synthesis and the study of their biological activity.4 Regarding to the molecular basis of 
this strong inhibitory activity, it was postulated that azepanes could probably adapt 
better to the active site of glycosidases due to them being structurally more flexible than 








2c: R2=R3=H; R1=OH; R4=NHAc












1 a: X=OH, b: X=H
 
A number of 1,6-dideoxy-1,6-iminoheptitols 2, a novel family of polyhydroxylated 
azepanes that are higher homologues of deoxynojirimycin (1b), were prepared (Figure 
1).6 Some of these derivatives show potent and specific glycosidase inhibition; e.g., 
compound 2a is a potent and selective inhibitor of coffee bean α-galactosidase, 
compound 2b strongly inhibits bovine liver β-galactosidase and compounds 2c and 2d 
are inhibitors of β-acetyl-N-glucosaminidases. On the other hand, due to the unusual 
spatial distribution of the hydroxyl groups,7 these azepanes not only display a different 
inhibition profile compared to the previously reported polyhydroxylated azepanes, but 
they are also more prone to form hydrogen bonds with nitrogenated bases, thus 
improving their ability to bind to the minor groove of DNA.8 
As a continuation of our interest in novel synthetic approaches to iminosugars,9 here we 
describe the synthesis of tetrahydroxyazepane 9 from shikimic acid (3). 
 
RESULTS AND DISCUSSION. 
In connection with our previous work in iminosugars, we present here our recent results 
concerning to the syntheses of the tetrahydroxyazepane 9 from shikimic acid (3). 
Thus, as stated in the Scheme 1, protected 1-hydroxymethyl-3,4,5-cyclohexenetriol (5) 
was prepared from shikimic acid (3) via its methyl ester derivative 4. This key 
intemediate compound was transformed into the expected azepane 9 in three steps, 
including protection of its hydroxy groups, ozonolysis, reductive amination and final 
deprotection.  
This novel synthetical approach to azepane 9 clearly improves a previous similar 

































Scheme 1. Conditions.- (i) a) MeOH, H2SO4; b) 2,2-dimethoxypropane, PTSA, acetone.
(ii)  DIBAL-H, THF. (iii) TBDMSCl, imidazole, DMF. iv) O3, PPh3; (v) BnNH2, NaBH(OAc)3. 
(vi) a) H2, Pd/C, b) 2N HCl, MeOH
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